drugset / Trial / NCT00042822

FR901228 in Treating Patients With Myelodysplastic Syndrome, Acute Myeloid Leukemia, or Non-Hodgkin's Lymphoma

NCT00042822

Treatment

Summary

RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of FR901228 in treating patients who have myelodysplastic syndrome, acute myeloid leukemia, or non-Hodgkin's lymphoma.

Timeline

Start
2002-05
Primary completion
2005-03
Completion

Drugs

EvaluationDrugModalityDoseRoute
Subject Romidepsin Peptide 18 mg/m2 Intravenous